The VUB spin-off Precirix, the leader in precision radiopharmaceuticals, has announced the launch of an Academic Access Program for its proprietary imaging tracer, CAM-FAP-Ga-68.
The program aims to expand access to this innovative radiopharmaceutical, enabling physicians and researchers to explore its potential in oncology imaging. CAM-FAP-Ga-68 targets fibroblast activation protein (FAP), overexpressed in various tumour types, making it a valuable tool in cancer diagnosis.
This initiative underscores Precirix's commitment to advancing clinical research and improving patient care through collaboration.
Click here for more information on the Academic Access Program.